PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pacira BioSciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$36.34+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.46B
- P/E (TTM)
- 103.8
- Dividend yield
- –
Pacira BioSciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $722.85M | $697.19M | $672.25M | $664.15M | $538.97M | $426.61M | $418.93M | $332.43M | $284.34M | – | 99.5% | +3.7% |
| EXPAREL | $575.13M | $548.96M | $538.12M | $536.90M | $506.52M | $413.34M | $407.88M | $331.11M | $282.91M | $265.80M | 79.2% | +4.8% |
| ZILRETTA | $116.63M | $118.09M | $111.10M | $105.52M | $12.68M | $0 | $0 | – | – | – | 16.1% | -1.2% |
| iovera | $24.18M | $22.81M | $19.69M | $15.26M | $16.16M | $8.82M | – | – | – | – | 3.3% | +6.0% |
| Bupivacaine liposome injectable suspension | $6.91M | $7.32M | $3.34M | $6.48M | $3.61M | $4.46M | $3.15M | – | – | – | 1.0% | -5.6% |
| Royalty revenue | $3.56M | $3.78M | $2.73M | $2.67M | $2.44M | $3.03M | $2.10M | $1.85M | $1.90M | – | 0.5% | -5.9% |
| Other product sales | – | – | – | – | – | – | – | $1.32M | $1.44M | $4.27M | – | – |
| EXPAREL | – | – | – | – | – | $417.80M | $411.03M | $332.43M | $283.25M | – | – | – |
| iovera | – | – | – | – | $16.16M | $8.82M | $7.90M | $0 | $0 | – | – | – |
| Depo Cyte | – | – | – | – | – | – | $0 | $0 | $1.09M | – | – | – |
| Collaborative licensing and milestone revenue | – | – | $0 | $0 | $125.00K | $0 | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Pacira BioSciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.